 |
| Boston Globe |
Based on a composite score derived from financial data for the four quarters ending December 31, 2010, ZOLL was ranked 39 among Massachusetts-based companies whose stock is publicly traded, moving up from number 67 a year earlier. It is one of eight medical device companies to have been included in the Globe 100, which is now in its 23rd year. This year, only 90 Massachusetts companies were named to the Globe 100 list, serving as a lingering reminder of the challenging economic climate.
“The Massachusetts economy is recovering and the companies on the Globe 100 are leading the way," said Shirley Leung, Boston Globe Business Editor. To qualify for this year’s Globe 100, a company must have been public for the entire 2010 calendar year and have reported a positive net income for both 2009 and 2010. Companies are ranked on four criteria: return on average equity, one-year percentage change in revenue, one-year percentage change in profit margin, and 2010 revenue.
“We are extremely pleased to be named again this year and rank as number 39 in the company of Massachusetts’ strongest business organizations from various sectors,” said Richard A. Packer, Chief Executive Officer of ZOLL. “We are also delighted that based on our performance we continue to rise in the rankings despite some of the challenges in health care spending over the last year.”
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL (zoll.com) develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe.
Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, our belief regarding revenues, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010 and updated in the Company’s Quarterly Reports on Form 10-Q filed subsequently to the Form 10-K. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.
Investor Contact:
A. Ernest Whiton, Chief Financial Officer
ZOLL Medical Corporation
P: +1 (978) 421-9655
No comments:
Post a Comment